THE EFFECT OF MULTIPLE DOSAGE ON THE KINETICS OF GLUCURONIDATION AND SULFATION OF DIFLUNISAL IN MAN

被引:20
作者
VERBEECK, RK
LOEWEN, GR
MACDONALD, JI
HERMAN, RJ
机构
[1] UNIV SASKATCHEWAN,COLL PHARM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA
[2] UNIV SASKATCHEWAN,COLL MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA
关键词
D O I
10.1111/j.1365-2125.1990.tb03654.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The single (250 and 500 mg) and multiple dose (250 and 500 mg twice daily for 15 days) pharmacokinetics of diflunisal were compared in young volunteers. 2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/− 1.2 and 4.2 +/− 0.7 ml min‐1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/− 3.1 and 9.9 +/− 2.0 ml min‐1 for the 250 and 500 mg single doses, respectively). 3. The partial metabolic clearances of diflunisal by acyl and phenolic glucuronide formation were lowered significantly (greater than 50%) after multiple dose administration. 4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/− 2.8 and 9.1 +/− 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/− 3.1 and 15.9 +/− 3.6% following the 250 and 500 mg twice daily regimens. The partial metabolic clearance of diflunisal by sulphate conjugation was unchanged following multiple dose administration. 5. The plasma protein binding of diflunisal was concentration‐dependent. Analysis of unbound plasma clearances of diflunisal showed that its total plasma clearance following 500 mg twice daily was affected by both saturable glucuronidation and concentration‐dependent plasma binding. 1990 The British Pharmacological Society
引用
收藏
页码:381 / 389
页数:9
相关论文
共 24 条
[1]  
BJORNSSON TD, 1979, CLIN PHARMACOL THER, V26, P540
[2]  
DAVIES RO, 1983, PHARMACOTHERAPY S1, V3, pS9
[3]   REACTIVITY CONSIDERATIONS IN THE ANALYSIS OF GLUCURONIDE AND SULFATE CONJUGATES OF DIFLUNISAL [J].
DICKINSON, RG ;
KING, AR .
THERAPEUTIC DRUG MONITORING, 1989, 11 (06) :712-720
[4]   INFLUENCE OF RENAL-FAILURE, RHEUMATOID-ARTHRITIS AND OLD-AGE ON THE PHARMACOKINETICS OF DIFLUNISAL [J].
ERIKSSON, LO ;
WAHLINBOLL, E ;
ODARCEDERLOF, I ;
LINDHOLM, L ;
MELANDER, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (02) :165-174
[6]  
FURST DE, 1979, CLIN PHARMACOL THER, V26, P380
[7]   ISOLATION AND IDENTIFICATION OF THE REARRANGEMENT PRODUCTS OF DIFLUNISAL 1-O-ACYL GLUCURONIDE [J].
HANSENMOLLER, J ;
CORNETT, C ;
DALGAARD, L ;
HANSEN, SH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1988, 6 (03) :229-240
[8]  
Houston JB, 1982, PHARMACOL THERAPEUT, V15, P521
[9]   DISPOSITION AND IRREVERSIBLE PLASMA-PROTEIN BINDING OF TOLMETIN IN HUMANS [J].
HYNECK, ML ;
SMITH, PC ;
MUNAFO, A ;
MCDONAGH, AF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :107-114
[10]   SIMULTANEOUS DETERMINATION OF ZOMEPIRAC AND ITS MAJOR METABOLITE ZOMEPIRAC GLUCURONIDE IN HUMAN-PLASMA AND URINE [J].
LANGENDIJK, PNJ ;
SMITH, PC ;
HASEGAWA, J ;
BENET, LZ .
JOURNAL OF CHROMATOGRAPHY, 1984, 307 (02) :371-379